Dr. Alireza Eghtedar, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 217
Licensed in Texas since 2011, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CO license 55429 (first issued 2015; active) -
Emergency Medicine Physician
TX license N9365 (first issued 2011; active) -
Internal Medicine Physician
CO license 55429 (first issued 2015; active) · MI license 4301099957
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- HCA Healthone Presbyterian St. Lukes Denver, CO
Medical groups
- Healthone Clinic Services - Oncology Hematology LLC (47 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 217
- Services billed
- 35,298
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 8,100 | 26 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 1,470 | 21 |
| Injection, magnesium sulfate, per 500 mg | 624 | 28 |
| Insertion of needle into vein for collection of blood sample | 423 | 81 |
| Injection, ondansetron hydrochloride, per 1 mg | 232 | 14 |
| Established patient office or other outpatient visit, 40-54 minutes | 162 | 60 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 159 | 47 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 109 | 59 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 87 | 47 |
| Administration of chemotherapy into vein, 1 hour or less | 61 | 34 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Valacyclovir (valacyclovir hcl) Other prescribers in Denver, CO | 161 |
| Acyclovir Other prescribers in Denver, CO | 100 |
| Jakafi (ruxolitinib phosphate) | 84 |
| Sirolimus | 48 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Denver, CO | 47 |
| Lisinopril Other prescribers in Denver, CO | 35 |
| Eliquis (apixaban) Other prescribers in Denver, CO | 31 |
| Calquence (acalabrutinib maleate) | 29 |
| Dexamethasone Other prescribers in Denver, CO | 28 |
| Fluconazole Other prescribers in Denver, CO | 27 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 27 payments worth $753 in total to this clinician.
| AbbVie Inc. | $322 |
|---|---|
| Pfizer Inc. | $135 |
| Sumitomo Pharma America, Inc. | $73.16 |
| Astellas Pharma US Inc | $59.17 |
| Sanofi-aventis U.S. LLC | $23.29 |
| Invivyd Inc | $22.69 |
| Regeneron Healthcare Solutions, Inc. | $22.61 |
| Incyte Corporation | $21.70 |
| Food and Beverage | $753 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $177,400 in research payments for these studies, mostly to the institutions running them.
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc. · Recruiting · NCT04988555 - TAK-012-1501
Takeda Pharmaceuticals U.S.A., Inc. - A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AM…
Astellas Pharma Global Development - A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
National Marrow Donor Program - Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic …
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.